Myeloproliferative Neoplasms

Outcomes were mixed for momelotinib in topline results from 2 phase III myelofibrosis trials announced by Gilead Sciences, the company developing the investigational JAK1/2 inhibitor.

Both myelofibrosis and polycythemia vera are myeloproliferative neoplasms with very specific characteristics and treatment strategies.

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Ruben Mesa, MD, discussed the latest NCCN treatment guidelines for myelofibrosis and emerging treatments in the field.

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

The future of imetelstat as a treatment for patients with myelodysplastic syndromes is uncertain following an update on 2 clinical trials.

Currently available therapies offer meaningful clinical benefits to patients with myelofibrosis, but achieving remission will likely require new molecules targeting different pathways.